(Press-News.org) BOSTON, March 29, 2023 — The Institute for Protein Innovation (IPI), a nonprofit research organization, announced today a $210 million gift from Tim Springer, Ph.D., veteran entrepreneur and professor at Harvard Medical School and Boston Children’s Hospital, who founded IPI in 2017 with Andrew Kruse, Ph.D. The gift will advance protein science and accelerate research to improve human health.
The philanthropic gift—made by Springer, his wife Chafen Lu, Ph.D., and their children—adds to previous gifts of $40 million to IPI from Springer himself. It establishes an endowment that redefines IPI’s capacity to scale, enabling it to more rapidly achieve three ambitious objectives: providing high-quality antibodies and other protein-based tools to the scientific community, advancing protein science through investigator-driven research, and augmenting the education of life scientists.
“This gift is unmistakably transformative,” says Ken Fasman, Ph.D., President and CEO of IPI. “Thanks to Tim’s commitment, IPI will be able to take on more challenging problems in protein science that academia and industry cannot or will not. We now have the potential to impact biomedical research at a greater scale and duration.”
While companies have painstakingly developed therapeutic antibodies as blockbuster drugs, these efforts have not extended to research antibodies, which are used to recognize and attach to biomolecules to discover new biology, understand biological mechanisms and pinpoint the molecular origins of human diseases. As a result, innovation that could lead to additional drugs has suffered. Issues with antibody quality and reproducibility continue to hamper life sciences research, and many patients are left without an understanding of their diseases that could lead to transformative therapies.
“I founded IPI on the premise that a foundry for protein tools, and most importantly antibodies, would help scientists make discoveries, and possibly new therapeutics, for years to come; my gift will help realize this vision,” says Dr. Springer. “IPI is my legacy project and recognizes the role that monoclonal antibodies have played in my discovery and basic research.”
In its first and largest effort to date, the Institute built a high throughput platform that generates synthetic antibodies, specifically binding to secreted and cell surface receptors—the targets of most therapeutics. Eventually, IPI antibodies could allow researchers to more precisely link genes to diseases, helping the life sciences realize the full potential of the Human Genome Project.
“Knowledge about proteins is critical to connect a gene to its function in the body, and Tim’s pioneering support makes it possible for IPI to harness the full power of protein science to extend the successes of genomics in understanding human disease,” says Dr. Fasman, who led the Human Genome Database’s informatics team from 1992 to 1996.
Dr. Springer’s philanthropic investment in IPI stems from his early career as a postdoctoral fellow in the laboratory of César Milstein, who invented a technique to generate monoclonal antibodies that later won him and Georges Köhler the Nobel Prize.
At Harvard Medical School, Dr. Springer later used monoclonal antibodies to discover and study cell surface receptors. The work most recently earned him, along with Erkki Ruoslahti and Richard Hynes, the prestigious Albert Lasker Award for Basic Medical Research for their discovery of integrins, involved in the recognition, attachment and trafficking of cells in the body.
Dr. Springer’s efforts also kickstarted the launch of his first company, LeukoSite, in 1992. Its monoclonal antibody inhibitor resulted in the blockbuster drug vedolizumab, known commercially as Entyvio. In 1999, Millennium Pharmaceuticals, now owned by Takeda Pharmaceutical Company, acquired LeukoSite for stock that later appreciated to $3 billion.
IPI is Dr. Springer’s effort to back the science that served as the backbone of his career. This philanthropy was made possible by his entrepreneurial success, including his acclaimed role as a founding investor in Moderna in 2010. Springer has previously endowed professorships and chairs at Harvard Medical School, Boston Children's Hospital and the University of California, Berkeley.
By founding and continuing to support IPI, Dr. Springer has built the infrastructure for the Institute’s sustainability that will enable leadership to continue to prioritize scientific impact as its mission, including designing antibodies to target proteins that have so far eluded scientific understanding. IPI’s nonprofit model will allow for the characterization and distribution of those antibodies to life sciences communities.
IPI Surfacing Symposium
To celebrate its new chapter of growth, IPI will host its first symposium, IPI Surfacing, on Thursday, June 15, 2023, on the Harvard Medical School campus. Registration is open for the daylong event, convening top experts on cell surface receptor biology.
Learn more and register for IPI Surfacing here.
About the Institute for Protein Innovation
The Institute for Protein Innovation is pioneering a new approach to scientific discovery and collaboration. As a nonprofit research institute, we provide the biomedical research community with synthetic antibodies and deep protein expertise, empowering scientists to explore fundamental biological processes and pinpoint new targets for therapeutic development. Our mission is to advance protein science to accelerate research and improve human health. For more information, visit proteininnovation.org or follow us on social media @ipiproteins.
Harvard professor and entrepreneur Tim Springer donates $210 million to the Institute for Protein Innovation
ELSE PRESS RELEASES FROM THIS DATE:
New research prizes will give $2.5 million to top scientists in Texas
DALLAS – Texas scientists will receive $2.5 million in funding to advance their research thanks to a new prize program from Lyda Hill Philanthropies and TAMEST (Texas Academy of Medicine, Engineering, Science and Technology). The Hill Prizes, funded by Lyda Hill Philanthropies, will accelerate high-risk, high-reward research ideas with significant potential for real-world impact. The Prizes will celebrate top Texas innovators and researchers whose work could significantly impact science and society in five categories: Medicine, Engineering, Biological Sciences, Physical Sciences ...
Morressier joins the fight for science with federated integrity suite for authors and publishers
Berlin and Washington DC, May 24, 2023 – Morressier announced today an integrity suite that will be offered as part of its end-to-end platform, designed to increase the quality of and trust in the outputs of scientific research. Pre-flight checks for authors will flag potential quality issues, check for completeness of submissions, and provide recommendations for improvements in areas such as language. Publishers using the Morressier platform now have access to a powerful suite of automated tools to help them identify integrity issues early and at scale. Plagiarism detection tools in the Morressier platform, for instance, indicate phrases in submissions that may ...
SEngine Precision Medicine demonstrates potential of PARIS® Test to find unexpected therapeutic options for treating cancer
SEngine Precision Medicine, the precision oncology innovator matching patients to medicines based on their own tumor samples, announces the publication of a new case report showing a patient’s remarkable response to an off-label therapy identified by its PARIS® Test. Despite standard-of-care chemotherapy and two surgeries, the patient’s low-grade serous ovarian cancer (LGSOC) was progressing and her prognosis was terminal. But by testing a range of therapies in organoids grown from the patient’s own tumor sample, SEngine’s PARIS® Test identified as ...
Logging on for health: More older adults use patient portals, but access and attitudes vary widely
Far more older adults these days log on to secure websites or apps to connect with their health information or have a virtual health care appointment, compared with five years ago, a new poll shows. Overall, 78% of people aged 50 to 80 have used at least one patient portal, up from 51% in a poll taken five years ago, according to findings from the University of Michigan National Poll on Healthy Aging. Of those with portal access, 55% had used it in the past month, and 49% have accounts on more than one portal. But the poll also reveals major disparities, with some groups of older adults less likely to use patient portals, or more likely ...
Life stressors may contribute to multiple sclerosis flares, disability
A Michigan Medicine-led study finds that stressors across the lifespan — including poverty, abuse and divorce — are associated with worsening health and functional outcomes for people with multiple sclerosis. Using survey data from more than 700 people with MS, researchers discovered that stressful events occurring both in childhood and adulthood contributed significantly to participants’ level of disability. The results are published in Brain and Behavior. “MS is the leading cause of non-traumatic ...
Existing drugs point to first treatment for strokes linked to dementia
People who experience a type of stroke linked with nearly half of all dementias could be treated for the first time by repurposing two cheap and common drugs, a trial shows. Researchers found that isosorbide mononitrate and cilostazol, which are already used to treat other heart and circulatory diseases, can safely improve the debilitating outcomes people experience after lacunar stroke. The two drugs, which were found to be even more effective when used in combination, could be available as a treatment for lacunar strokes within five years, if the results are ...
Long or short menstrual cycles linked to higher risk of CVD including atrial fibrillation
Research Highlights: An analysis of data for more than 58,000 women in the U.K. Biobank found that both short (less than 21 days) or long (more than 35 days) menstrual cycles were associated with the development of cardiovascular disease, heart attack or atrial fibrillation (AFib). Short or long menstrual cycle length was associated with a 19% higher risk of heart disease among those women compared to women with menstrual cycle length between 22 to 34 days. Irregular menstrual cycle length was associated with a 40% higher risk of atrial ...
Physical activities like a daily, 20-minute walk may help reduce disparities in heart health
Statement Highlights: Addressing low levels of physical activity among people in some targeted groups has the potential to improve equity in cardiovascular health. Physical activity levels are lower among some population groups known to have higher cardiovascular disease risk, including adults who are older, female, Black, have depression, have disabilities, have lower socioeconomic status or live in rural areas. It’s important to improve resources and opportunities to decrease barriers to physical activity. Physical activity initiatives should engage the community and ...
Cleft lip caused by combination of genes and environment
A cleft lip or palate arises from the combined effects of genes and inflammatory risk factors experienced during pregnancy, such as smoking or infections, finds a new study led by UCL researchers. The study, published in Nature Communications, has revealed for the first time how genetic and environmental factors come together to form a cleft lip or palate in a developing foetus. Cleft lip, with or without cleft palate, is the most common craniofacial malformation seen at birth, affecting one in 700 live births. It can have devastating ...
Study finds association between long-term exposure to air pollution and severe COVID-19
A long history of exposure to air pollution is associated with a higher risk of developing severe disease, admission to hospital or an intensive care unit (ICU) and death by COVID‑19 according to a study led by the Barcelona Institute for Global Health (ISGlobal), a research centre supported by the ”la Caixa” Foundation. The study, published in the journal Nature Communications, was based on a large cohort of 4,660,502 adults resident in Catalonia in 2020, the year the Spanish autonomous community had a high incidence of COVID-19. The ...